Bausch Health (BHC)
(Delayed Data from NYSE)
$8.71 USD
+0.09 (1.04%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.72 +0.01 (0.11%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.71 USD
+0.09 (1.04%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.72 +0.01 (0.11%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
Zacks News
Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris
by Zacks.com
Bausch (BHC) advances its dermatology portfolio with the FDA approval of Altreno for acne vulgaris.
Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well
by Zacks Equity Research
Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
Bausch Health (BHC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 14.81% and 3.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Can Tenet Healthcare (THC) Keep Earnings Beat Alive in Q2?
by Zacks Equity Research
Tenet Healthcare (THC) is likely to repeat its success story in Q2 on the back of a strong performance at the Conifer segment as well as its key initiatives.